Covered recipient · General Payments record
FEHMIDA ZAHABI
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$9,213.79
255 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $4,080.41 | 251 |
| Consulting Fee | $3,294.00 | 2 |
| Honoraria | $1,800.00 | 1 |
| Education | $39.38 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,860.54 | 15 |
| PFIZER INC. | $2,190.90 | 26 |
| Janssen Biotech, Inc. | $1,132.23 | 24 |
| AbbVie Inc. | $844.12 | 54 |
| Amgen Inc. | $783.07 | 60 |
| GlaxoSmithKline, LLC. | $447.82 | 16 |
| E.R. Squibb & Sons, L.L.C. | $272.67 | 14 |
| Lilly USA, LLC | $195.90 | 15 |
| Aurinia Pharma U.S., Inc. | $149.85 | 12 |
| Genentech USA, Inc. | $102.01 | 5 |
| UCB, Inc. | $67.18 | 4 |
| Horizon Therapeutics plc | $45.69 | 3 |
| AstraZeneca Pharmaceuticals LP | $39.71 | 2 |
| Alexion Pharmaceuticals, Inc. | $22.64 | 1 |
| Radius Health, Inc. | $18.72 | 1 |
| Eisai Inc. | $14.93 | 1 |
| Organon LLC | $13.69 | 1 |
| Mallinckrodt Hospital Products Inc. | $12.12 | 1 |
Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FEHMIDA ZAHABI
NPI 1740397603 · CMS profile ID 305709
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
PLANO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1740397603?year=2021&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FEHMIDA ZAHABI, NPI 1740397603, CMS profile ID 305709. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740397603?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). FEHMIDA ZAHABI, NPI 1740397603, CMS profile ID 305709. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740397603?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- FEHMIDA ZAHABI, NPI 1740397603, CMS profile ID 305709, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–255 of 255 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740397603?year=2021&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
255 matching records · $9,213.79 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–255 of 255.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Radius Health, Inc. | $18.72 | 01/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830729349 | CMS |
| AbbVie Inc. | $3.91 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796298219 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.68 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783402209 | CMS |
| Lilly USA, LLC | $11.08 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819085157 | CMS |
| Lilly USA, LLC | $1.50 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819145517 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $263,516.83 | 63 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $416,620.60 | 69 |
| PY2023 | Recipient | $1,098.96 | 7 |
| PY2023 | Principal investigator | $436,116.90 | 71 |
| PY2022 | Principal investigator | $373,537.01 | 72 |
| PY2021 | Principal investigator | $278,146.55 | 75 |
| PY2020 | Principal investigator | $329,485.34 | 98 |
| PY2019 | Recipient | $254.48 | 5 |
| PY2019 | Principal investigator | $378,141.40 | 76 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
63 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $134.66 | 12/31/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIATES INC | A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202533211 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,113.00 | 12/22/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369379 |
| Principal investigator 1 | ABBVIE INC. | $2,863.45 | 12/04/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202527810 |
| Principal investigator 1 | ABBVIE INC. | $2,918.85 | 12/04/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202527812 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $187.19 | 12/03/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289164 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $53.78 | 12/03/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289166 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 11/26/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202525688 |
| Principal investigator 1 | ABBVIE INC. | $4,410.00 | 11/26/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202525690 |
| Principal investigator 1 | ABBVIE INC. | $1,509.30 | 11/25/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202525318 |
| Principal investigator 1 | ABBVIE INC. | $893.63 | 11/25/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202525328 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 11/25/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202525330 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 11/20/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202524876 |
| Principal investigator 1 | ABBVIE INC. | $900.00 | 11/20/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202524884 |
| Principal investigator 1 | ABBVIE INC. | $2,916.00 | 11/20/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202525010 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $18.55 | 11/20/2025 | Non-covered Recipient Entity Trinity Universal Research Associates | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | No dispute reported | 06/30/2026 | 1235992869 |
| Principal investigator 1 | ABBVIE INC. | $5,018.25 | 11/04/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202520595 |
| Principal investigator 1 | ABBVIE INC. | $12,971.20 | 11/04/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202520637 |
| Principal investigator 1 | ABBVIE INC. | $6,385.05 | 11/04/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202521109 |
| Principal investigator 1 | ABBVIE INC. | $3,834.00 | 10/16/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202517207 |
| Principal investigator 1 | ABBVIE INC. | $625.00 | 10/16/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202517209 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,673.20 | 10/15/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286941 |
| Principal investigator 1 | ABBVIE INC. | $3,312.00 | 10/14/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202516661 |
| Principal investigator 1 | ABBVIE INC. | $3,228.00 | 10/09/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202514857 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,388.00 | 10/03/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286299 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,932.00 | 09/29/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369407 |
| Principal investigator 1 | ABBVIE INC. | $5,401.05 | 09/03/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202507563 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,799.73 | 09/03/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223285019 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 08/20/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223284421 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500.00 | 08/20/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223284423 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,450.00 | 08/11/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369399 |
| Principal investigator 1 | ABBVIE INC. | $4,324.00 | 08/05/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202502016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $976.00 | 07/07/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369387 |
| Principal investigator 1 | ABBVIE INC. | $11,020.35 | 07/02/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202495521 |
| Principal investigator 1 | ABBVIE INC. | $2,928.25 | 07/02/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202495523 |
| Principal investigator 1 | ABBVIE INC. | $7,341.30 | 07/02/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202495525 |
| Principal investigator 1 | ABBVIE INC. | $3,607.35 | 06/03/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202489013 |
| Principal investigator 1 | ABBVIE INC. | $464.30 | 06/03/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202489015 |
| Principal investigator 1 | ABBVIE INC. | $2,278.80 | 06/03/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202489017 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,928.00 | 06/02/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369355 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,933.00 | 05/21/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223279992 |
| Principal investigator 1 | ABBVIE INC. | $1,882.45 | 05/06/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202481739 |
| Principal investigator 1 | ABBVIE INC. | $6,420.80 | 05/06/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202481795 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,823.00 | 04/28/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369362 |
| Principal investigator 1 | Eli Lilly and Company | $20,700.00 | 04/22/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIATES INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187891492 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,933.00 | 04/18/2025 | Non-covered Recipient Entity CLINITIATIVE HEALTH RESEARCH | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223278476 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,057.00 | 04/04/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIATES INC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192175075 |
| Principal investigator 1 | ABBVIE INC. | $3,526.80 | 04/03/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202469307 |
| Principal investigator 1 | ABBVIE INC. | $3,403.45 | 04/03/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202469482 |
| Principal investigator 1 | ABBVIE INC. | $4,256.70 | 04/03/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202469487 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,000.00 | 04/02/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIATES INC | A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E | No dispute reported | 06/30/2026 | 1192175071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,912.00 | 03/31/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369371 |
| Principal investigator 1 | ABBVIE INC. | $5,734.20 | 03/06/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202458601 |
| Principal investigator 1 | ABBVIE INC. | $10,619.30 | 03/06/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202458720 |
| Principal investigator 1 | ABBVIE INC. | $6,067.05 | 03/06/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202458913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,128.00 | 03/03/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369414 |
| Principal investigator 1 | ABBVIE INC. | $4,713.00 | 02/05/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202444842 |
| Principal investigator 1 | ABBVIE INC. | $3,065.80 | 02/05/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202444872 |
| Principal investigator 1 | ABBVIE INC. | $4,569.90 | 02/05/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202446531 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,061.00 | 01/27/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT ES INC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175369394 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,800.00 | 01/27/2025 | Non-covered Recipient Entity Trinity Universal Research Associat | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226146304 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $18,529.59 | 01/21/2025 | Non-covered Recipient Entity Trinity Universal Research Associates | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1235992867 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 01/16/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | No dispute reported | 06/30/2026 | 1202439302 |
| Principal investigator 1 | ABBVIE INC. | $3,776.55 | 01/02/2025 | Non-covered Recipient Entity TRINITY UNIVERSAL RESEARCH ASSOCIAT | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | No dispute reported | 06/30/2026 | 1202436038 |